Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090376 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT00090376 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 240 participants.
The verdict
NCT00090376, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
In this phase II study, an investigative (not approved by the FDA) drug called GPI 1485 is being assessed to see if it can help preserve erectile function after prostatectomy.
Interventions
- DRUG GPI 1485
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2003-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090376
The ClinicalTrials.gov registry entry for NCT00090376 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GPI 1485 is the first listed.
NCT00090376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090376 about?
NCT00090376 is a clinical study titled "Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy". In this phase II study, an investigative (not approved by the FDA) drug called GPI 1485 is being assessed to see if it can help preserve erectile function after prostatectomy.
What is the current status of trial NCT00090376?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2003-12.
What interventions are being tested in trial NCT00090376?
The interventions under investigation include: GPI 1485 (DRUG).
Who is sponsoring clinical trial NCT00090376?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.